With this orphan designation for Retinitis and if we get decent LymPro data next Monday, we should blow past .10 cent by year end! How high will it go.....no one knows! That's the fun part about being in this kind of stock....irrational exuberance can kick in at any moment. But we are so undervalued anyway that we'd just be playing catch up to where we should already have been.
.20 cents isn't too far away. If ICON decides to pony up some money and make our agreement with them more "concrete," then the pps could go up much higher than .20 cents in January.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links